The latest Business updates from the science industry


by Heather Hobbs Strong investment continues for developer of Autoimmune Therapies


Biotech start-up Tridek-One focused on research and development of CD31 agonists to restore the immune balance, has closed a €16 million ($16.1 million) fi nancing round led by the Swiss VC Pureos Bioventures with the participation of new investors Bpifrance, through its InnoBio2 fund, and Bioqube Ventures (Belgium), as well as historical investors AdBio partners and Advent Life Sciences. The funds will primarily be used to identify development candidates against auto-immune diseases, to conduct IND-enabling studies and to further build the organisation. The company previously raised €3 million ($3.02 million) in a fi rst round in 2019 involving AdBio partners (FR) and Advent Life Sciences (UK).


Founded in 2018 by Dr Giuseppina Caligiuri and Professor Antonino Nicoletti, Researchers at INSERM Unit 1148 (Paris, France), with the support of historical investor AdBio partners, Tridek-One is developing a novel CD31 agonist approach to modulate immune activation for the treatment of autoimmune diseases.


The start-up has also appointed Laurence de Schoulepnikoff as Chief Executive Offi cer. Laurence is a seasoned pharma and biotech professional


with broad experience in transactions and R&D operations. She has worked in VC-funded biotech start-ups and mid-size private companies as well as large corporate organisations. She joined the company from AMAL Therapeutics, a leading Swiss biotechnology company focused on therapeutic cancer vaccines, where she spent the last three years as chief business offi cer and chief operating offi cer.


“I am delighted and grateful to have the opportunity to lead Tridek-One as we plan to reach important preclinical milestones and build a fi rst-class biotech organisation for the treatment of auto-immune diseases,” said Ms Schoulepnikoff.


Following the fundraising, Klaus Breiner of Pureos Bioventures, and Benoit Barteau of Bpifrance, are joining the company’s board of directors. Erik van den Berg, CEO of AM-Pharma, joins as independent chairman of the Board of Directors.


“It is a pleasure to join as Chairman whilst the company is building a great team, with a professional syndicate of international investors committing to decades of research by the team of Dr. Giuseppina Caligiuri and Professor Antonino Nicoletti,” commented Mr van den Berg.


Erik van den Berg


“There is still an important, unsatisfi ed medical need in many auto-immune diseases. Agonising immune inhibitory receptors like CD31 has the potential to rebalance the immune system without being more broadly immunosuppressive. We are excited to further translate this concept with Tridek-One through


European Project set to tackle RA through coordinated efforts


A new European consortium with aims to discover new ways to maximise the impact of prescription drugs for patients suffering from Rheumatoid Arthritis, has welcomed industry partner Daman, a digital healthcare company based in Copenhagen, Denmark.


Digital healthcare tools and biomarkers are expected to play a key role in the new SQUEEZE project which is focused on overcoming real-life


challenges of drug therapy by addressing behavioural and psychosocial aspects such as non-adherence, psychosocial burdens, perceptions, comorbidities and dosage of medicine.


Coordinated by the Medical University of Vienna, the consortium of 13 leading European organisations including university hospitals, research institutions and healthcare companies will conduct the 5-year project which is being co-funded by Horizon Europe. Due to start between late 2022 and early 2023, total funding for the project is 12m Euros.


Affecting more than 3 million patients in the EU and 17.6 million worldwide, Rheumatoid Arthritis (RA) is an autoimmune chronic disease with massive impact on patients’ quality of life with signifi cant socio- economic implications. New precision medicine tools are expected to emerge from the project.


Professor Daniel Aletaha


“The SQUEEZE project is a great privilege to join – I guess it is fair to characterise the consortium as a partnership of the leading and most well-respected European stakeholders within Rheumatoid Arthritis. Daman’s role in the SQUEEZE project will focus on development, implementation and pilot testing of digital therapeutics based on our novelty in building next generation healthcare solutions with precision medicine. By the end of the project a digital therapeutic tool utilising a recommendation engine for patients and healthcare professionals will be implemented,” said company CEO Andreas Dam.


One of the world’s most renowned rheumatology scientists, Professor at the Medical University of Vienna and President-Elect of The European League Against Rheumatism (EULAR) Daniel Aletaha commented: “Over the past decades promising new treatments for Rheumatoid Arthritis have been introduced. When successful, the SQUEEZE project will enable us to match patient and medical treatment in a signifi cantly more precise manner moving from a trial-and-error treatment regime to a brand-new and patient-focused innovative care model for Rheumatoid Arthritis. The SQUEEZE project has the potential to become a milestone for RA-patients as well as for precision medicine and precision health in general.”


Andreas Dam


More information online: ilmt.co/PL/Z2eK 58873pr@reply-direct.com


Laurence de Schoulepnikoff


its discovery and preclinical stages,” added Klaus Breiner, Managing Partner of Pureos Bioventures.


More information online: ilmt.co/PL/kqPD 58877pr@reply-direct.com


Funding Supports Biohub Partner


Early-stage life sciences venture capital group Coddle Creek Capital (CCC) has announced a multi-million dollar acquisition investment in Eremid Genomic Services LLC, a company focused on provision of genomics data in the areas of human health, agriculture, plant based nutrition and longevity. Originally spun out as the commercial arm of the David H. Murdock Research Institute, the new management structure will drive the company forward as a high-end, scientifi cally driven genomics partner with enhanced ability to deliver high-quality data using the latest in genomics instruments and automation.


The company will be a key partner and resource for the rapidly growing biotech hub being built on the Institute’s North Carolina Research Campus and for the local and wider genomics community. With goals to provide access to and guidance on the use of rapidly-evolving Next Generation Sequencing technologies, the company’s experience in delivering complex genomics projects and bioinformatic analyses places it as the perfect CRO partner to meet this, said CCC.


In addition to Eremid, CCC has been a key investor, advisor and/or founder of several co-located companies that will form part of the expanding biotech hub, including:


BrightPath Labs: An advanced AI-driven drug manufacturer


Salubrent Pharma Services: An CDMO focused on advancing the aseptic sterile fi ll & fi nish formulation and manufacturing sector.


SNP Therapeutics: A Precision Nutrition company, spun out from the University of North Carolina Chapel Hill Nutritional Research Institute in Kannapolis, NC.


Julian Abery, Chief Business Offi cer at Eremid commented: “This is an exciting time of growth and development for us. With the support of Coddle Creek Capital, Eremid promises to become a best-in- class genomics CRO. We will deliver scientifi c excellence to our customers by leveraging decades of research experience and the latest technologies, while making no compromises in our processes. We will focus on areas that infl uence human health and longevity, including agbiotech, nutrition, and immunooncology research.”


More information online: ilmt.co/PL/WyeP 58869pr@reply-direct.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72